The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity - PubMed (original) (raw)
Comparative Study
. 2004 Mar;34(3):752-761.
doi: 10.1002/eji.200324427.
Affiliations
- PMID: 14991605
- DOI: 10.1002/eji.200324427
Free article
Comparative Study
The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity
Joseph Lustgarten et al. Eur J Immunol. 2004 Mar.
Free article
Abstract
The majority of tumor-associated antigens are aberrantly expressed or overexpressed normal gene products. Therefore, mechanisms responsible for self tolerance dampen immune responses against these antigens. To evaluate the effect that tolerance has on the immune responses against tumor antigens, we characterized the CD8+ T cell responses in neu mice. T cell responses against the A2.1/neu p369-377 and p773-782 peptides were evaluated in neu mice that were crossed with A2.1/Kb transgenic mice (A2 x neu). Tetramer binding and cytotoxic activity demonstrate that, compared to CTL from A2.1/Kb x FVB wild-type mice (A2 x FVB), CD8+ T cells from A2 x neu mice were of lower avidity for the peptides. Despite the fact that A2 x neu mice are tolerant, multiple immunizations with DC pulsed with the p369-377 or p773-782 peptides in the presence of IL-2 retarded tumor growth in A2 x neu mice, and immunizations in combination with the anti-OX40 mAb further enhanced the antitumor response. Taken together, these data indicate that low-avidity T cells for neu antigens persisting in A2 x neu mice have the capacity to develop antitumor responses as long as they are provided with efficient costimulation. These results underscore the potential role of low-avidity T cells in antitumor immunity and may offer an important component for vaccination immunotherapies.
Similar articles
- Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice.
Cuadros C, Dominguez AL, Lollini PL, Croft M, Mittler RS, Borgström P, Lustgarten J. Cuadros C, et al. Int J Cancer. 2005 Oct 10;116(6):934-43. doi: 10.1002/ijc.21098. Int J Cancer. 2005. PMID: 15856473 - Identification of cross-reactive peptides using combinatorial libraries circumvents tolerance against Her-2/neu-immunodominant epitope.
Lustgarten J, Dominguez AL, Pinilla C. Lustgarten J, et al. J Immunol. 2006 Feb 1;176(3):1796-805. doi: 10.4049/jimmunol.176.3.1796. J Immunol. 2006. PMID: 16424210 - Cooperative effect between immunotherapy and antiangiogenic therapy leads to effective tumor rejection in tolerant Her-2/neu mice.
Cuadros C, Dominguez AL, Frost GI, Borgstrom P, Lustgarten J. Cuadros C, et al. Cancer Res. 2003 Sep 15;63(18):5895-901. Cancer Res. 2003. PMID: 14522915 - Immunogenic HER-2/neu peptides as tumor vaccines.
Baxevanis CN, Sotiriadou NN, Gritzapis AD, Sotiropoulou PA, Perez SA, Cacoullos NT, Papamichail M. Baxevanis CN, et al. Cancer Immunol Immunother. 2006 Jan;55(1):85-95. doi: 10.1007/s00262-005-0692-3. Epub 2005 Oct 27. Cancer Immunol Immunother. 2006. PMID: 15948002 Free PMC article. Review. - Cellular immunity to the Her-2/neu protooncogene.
Kiessling R, Wei WZ, Herrmann F, Lindencrona JA, Choudhury A, Kono K, Seliger B. Kiessling R, et al. Adv Cancer Res. 2002;85:101-44. doi: 10.1016/s0065-230x(02)85004-7. Adv Cancer Res. 2002. PMID: 12374283 Review.
Cited by
- Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses.
Kalos M. Kalos M. Cancer Immunol Immunother. 2012 Jan;61(1):127-35. doi: 10.1007/s00262-011-1173-5. Epub 2011 Dec 1. Cancer Immunol Immunother. 2012. PMID: 22131062 Free PMC article. Review. - Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens.
Jordan KR, McMahan RH, Kemmler CB, Kappler JW, Slansky JE. Jordan KR, et al. Proc Natl Acad Sci U S A. 2010 Mar 9;107(10):4652-7. doi: 10.1073/pnas.0914879107. Epub 2010 Jan 26. Proc Natl Acad Sci U S A. 2010. PMID: 20133772 Free PMC article. - Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo.
Redmond WL, Gough MJ, Weinberg AD. Redmond WL, et al. Eur J Immunol. 2009 Aug;39(8):2184-94. doi: 10.1002/eji.200939348. Eur J Immunol. 2009. PMID: 19672905 Free PMC article. - Chronic chemoimmunotherapy achieves cure of spontaneous murine mammary tumors via persistent blockade of posttherapy counter-regulation.
Rowswell-Turner RB, Harden JL, Nair RE, Gu T, Kilinc MO, Egilmez NK. Rowswell-Turner RB, et al. J Immunol. 2011 Oct 15;187(8):4109-18. doi: 10.4049/jimmunol.1101136. Epub 2011 Sep 9. J Immunol. 2011. PMID: 21908736 Free PMC article. - In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line.
Santegoets SJ, Schreurs MW, Masterson AJ, Liu YP, Goletz S, Baumeister H, Kueter EW, Lougheed SM, van den Eertwegh AJ, Scheper RJ, Hooijberg E, de Gruijl TD. Santegoets SJ, et al. Cancer Immunol Immunother. 2006 Dec;55(12):1480-90. doi: 10.1007/s00262-006-0142-x. Epub 2006 Feb 9. Cancer Immunol Immunother. 2006. PMID: 16468034 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous